← Back to Search

Other

Potassium Nitrate (KNO3) for Heart Failure

Phase 2
Waitlist Available
Led By Payman Zamani, MD
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)
Awards & highlights

Study Summary

This study is evaluating whether a drug which is used to treat angina may help improve exercise capacity in heart failure patients.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Total Work Performed During a Maximal-effort Exercise Test From Phase 1 to Phase 2
Difference in Peak Oxygen Consumption (Vo2) Between KNO3 and KCl Phases
Secondary outcome measures
Effect of KNO3 on the Percent Change of Systemic Vasodilatory Response to Exercise: The Change in Systemic Vascular Resistance Reserve During Exercise During a Maximal Effort Exercise Test
Effect of Potassium Nitrate (KNO3) on Arterial Wave Reflections as Assessed by Wave Separation Analysis Using Tonometry and Doppler Flow Data
Effect of Potassium Nitrate (KNO3) on Augmentation Index
+8 more

Side effects data

From 2022 Phase 2 trial • 84 Patients • NCT02840799
21%
other
19%
stomach ache
14%
fatigue
10%
headache
9%
shortness of breath
8%
nausea
6%
swelling
4%
palpitations
4%
chest pain
4%
weakness
3%
vomiting
3%
bilateral knee pain
3%
insomnia
3%
shortness of breath during the peak exercise test
3%
gassiness
3%
fatigue during the peak exercise test
3%
diarrhea
1%
oral thrush
1%
rapid heart beat
1%
sore throat
1%
cough
1%
bronchitis
1%
skin irritation
1%
edema
1%
fever
1%
hypoglycemic episode
1%
creatinine increase
1%
lightheadedness
1%
positive orthostat
1%
aches in the joints
1%
leg cramps
1%
restlessness
1%
thigh cramps
1%
abnormal sensation of swallowing
1%
soreness
1%
dizziness
1%
hip pain
1%
o2 desaturation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Potassium Nitrate (KNO3)
Potassium Chloride (KCl)
Baseline Visit

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Potassium Nitrate (KNO3)Experimental Treatment1 Intervention
Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.
Group II: Potassium Chloride (KCl)Placebo Group1 Intervention
Potassium Chloride (KCl) is the placebo (control drug) in this trial. Potassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Potassium Nitrate (KNO3)
2016
Completed Phase 2
~90

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
2,005 Previous Clinical Trials
42,882,125 Total Patients Enrolled
42 Trials studying Heart Failure
7,430 Patients Enrolled for Heart Failure
Northwestern UniversityOTHER
1,586 Previous Clinical Trials
916,897 Total Patients Enrolled
20 Trials studying Heart Failure
4,219 Patients Enrolled for Heart Failure
Julio A Chirinos, MD, PhDStudy ChairUniversity of Pennsylvania
3 Previous Clinical Trials
61 Total Patients Enrolled
2 Trials studying Heart Failure
61 Patients Enrolled for Heart Failure

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)
2016. "Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02840799.
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top